Liver Neoplasms Clinical Trial
Official title:
Clinical Application of Preoperative Nutritional Support Package for Liver Cancer
NCT number | NCT04218253 |
Other study ID # | 20191226 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 1, 2019 |
Est. completion date | June 30, 2022 |
Objective:To confirm the effect of preoperative oral nutrition therapy on patients with
malnourished before liver cancer resection.
Study design:Prospective, randomized, controlled clinical study. Primary end point: incidence
of all complications 30 days after surgery.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 30, 2022 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - 1. Clinical diagnosis of primary liver cancer (including hepatocellular carcinoma, bile duct carcinoma, and mixed cell carcinoma) - 2. No contraindications for surgery - 3. Eastern Cooperative Oncology Group (ECOG) score of preoperative physical state <2 points - 4. Preoperative liver function score Child-Pugh = 6 points: total bilirubin = 3.0 mg / dl, albumin = 28 g / L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) = 5 times the upper limit of normal - 5. Voluntarily enter the study and sign the informed consent form, and communicate well with the researcher Exclusion Criteria: - 1. Patients who took fish oil supplements within 3 weeks before the study began - 2. Patients with severe nutritional risk: serious nutritional risk should be considered when combining any of the following conditions: weight loss > 10% within 6 months; digital pain score (NRS) score > 5 points; BMI <18.5 kg/m2 (all patients with severe nutritional risk undergo individualized supportive care); - 3. Patients with malignant tumors in other parts - 4. Patients who are pregnant or lactating - 5. Patients with mental and neurological disorders who cannot cooperate with medical staff - 6. Patients with severe diabetes or poor glycemic control - 7. Patients cannot tolerate nutritional preparations - 8. Other circumstances that the researcher considers inappropriate to participate in the study |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University cancer Instituteand Hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of complications at 30 days after surgery | Postoperative complications were defined by Clavien-Dindo. Grade 1: Any deviation from the normal postoperative course without the need for pharmacologic treatment or surgical, endoscopic, and radiologic interventions. Allowed therapeutic regimens are drugs as antiemetics, antipyretics, analgetics, and diuretics, and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade 2: Requiring pharmacologic treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. Grade 3: Requiring surgical, endoscopic, or radiologic intervention 3a: Intervention not under general anesthesia 3b: Intervention under general anesthesia Grade 4:Life-threatening complication (including CNS complications) requiring IC/ICU management. 4a: Single organ dysfunction (including dialysis) 4b: Multiple organ dysfunction Grade 5: Death as a result of complications |
up to 30 days after surgery | |
Secondary | Postoperative hospital stay | from the date of the operation to the date of discharge | up to 90 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
Not yet recruiting |
NCT03592550 -
The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
|
||
Not yet recruiting |
NCT02521129 -
A New Track Ablation Device for Liver Biopsy: A Feasibility Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02168608 -
Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
|
N/A | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Active, not recruiting |
NCT01177007 -
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
|
Phase 2 | |
Completed |
NCT00788697 -
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
|
Phase 3 | |
Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
Completed |
NCT00094003 -
Study of NS-9 in Patients With Liver Metastases
|
Phase 1 | |
Terminated |
NCT00051532 -
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT00001587 -
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
|
Phase 1 | |
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT03289273 -
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
|
||
Terminated |
NCT03349255 -
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03715517 -
Spinal Anesthesia For Enhanced Recovery After Liver Surgery
|
N/A | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01744054 -
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
|
Phase 1 | |
Active, not recruiting |
NCT02969096 -
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
|
Phase 2 |